Zhejiang East-Asia Pharmaceutical (605177.SH) subsidiary obtains European CEP certificate for flurbiprofen API
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that recently, its wholly-owned subsidiary Jiangxi Shanyuan Pharmaceutical Co., Ltd. received the Certificate of Suitability to the European Pharmacopoeia (CEP certificate) for flurbiprofen API issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Flurbiprofen is a nonsteroidal anti-inflammatory drug, clinically mainly indicated for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, etc., and can also be used for symptomatic treatment of soft tissue disorders (such as sprains and strains) and mild to moderate pain (such as dysmenorrhea, postoperative pain, and toothache, etc.).
Zhejiang East-Asia Pharmaceutical (605177.SH) announced that recently, its wholly-owned subsidiary Jiangxi Shanyuan Pharmaceutical Co., Ltd. received the Certificate of Suitability of the European Pharmacopoeia (CEP certificate) for flurbiprofen API issued by the European Directorate for the Quality of Medicines & HealthCare (EDQM). Flurbiprofen is a nonsteroidal anti-inflammatory drug, clinically mainly indicated for rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, etc., and can also be used for symptomatic treatment of soft tissue diseases (such as sprains and strains) and mild to moderate pain (such as dysmenorrhea, postoperative pain, toothache, etc.).
Related Articles
NYOCOR (600821.SH) plans to jointly invest in and construct the Weihe coal power project with related party Jinrong Guojin.
HK Stock Market Move | IMPACT THERAP-B (07630) rose more than 10% in late trading; the EU marketing application for senaparib is expected to be approved this month.
Humanwell Healthcare (600079.SH): HW201877 capsules enter Phase II clinical trial study
NYOCOR (600821.SH) plans to jointly invest in and construct the Weihe coal power project with related party Jinrong Guojin.
HK Stock Market Move | IMPACT THERAP-B (07630) rose more than 10% in late trading; the EU marketing application for senaparib is expected to be approved this month.
Humanwell Healthcare (600079.SH): HW201877 capsules enter Phase II clinical trial study
